Although pharmaceutical counterfeiting incidents can be traced back thousands of years, it has been downplayed and even dismissed by pharmaceutical manufacturers in the past. That has changed. Pharmaceutical firms are newly dedicated to eradicate counterfeits globally and spending more money on...

The debate over access to medicines has principally centered on pharmaceutical patents and prohibitively high drug prices. Although a less recognized problem, counterfeit pharmaceuticals are certainly a more insidious barrier to access. Pharmaceutical counterfeiting is an invisible threat, not...

The resource-based view of the firm suggests that direct control over unique assets can form the basis of sustained competitive advantage. In contrast, the papers presented in this Special Issue examine the payoffs to cross-boundary resource management. These papers demonstrate the potency of...